Cytological features of double-hit lymphoma with concurrent BCL2/IGH and MYC/IGH—A case report—

2014 ◽  
Vol 53 (6) ◽  
pp. 446-452
Author(s):  
Yosuke SASAKI ◽  
Koji KISHIMOTO ◽  
Takashi KITAMURA ◽  
Eisuke SHIOZAWA ◽  
Mayumi HOMMA ◽  
...  
Keyword(s):  
Case Report ◽  
Double Hit Lymphoma ◽  
Cytological Features ◽  
Double Hit

scholarly journals Double-Hit Lymphoma at Second Relapse of Burkitt-Like Lymphoma : A Case Report

2011 ◽  
Vol 51 (1) ◽  
pp. 43-47 ◽  
Author(s):  
Hiroaki Tanaka ◽  
Shinichiro Hashimoto ◽  
Daijiro Abe ◽  
Shio Sakai ◽  
Toshiyuki Takagi
Keyword(s):  
Case Report ◽  
Double Hit Lymphoma ◽  
Double Hit

Double-Hit Lymphoma Presenting as Primary Renal Lymphoma: A Case Report

2013 ◽  
Vol 1 (2) ◽  
pp. 93
Author(s):  
Vikas Mehta ◽  
Chad Ellimottil ◽  
Jodi Speiser ◽  
Milind Velankar ◽  
Guliz Barkan
Keyword(s):  
Case Report ◽  
Renal Lymphoma ◽  
Double Hit Lymphoma ◽  
Double Hit

scholarly journals Double-Hit Lymphoma (MYC and BCL6) with Involvement of Skull and Adnexal Lesions: A Case Report and a Review of the Literature

2018 ◽  
Vol 19 ◽  
pp. 1035-1041 ◽  
Author(s):  
Hamza Minhas ◽  
Cherif Abdelmalek ◽  
Marium Khan ◽  
James E. O\'Donnell ◽  
Vladimir Gotlieb ◽  
...  
Keyword(s):  
Case Report ◽  
Review Of The Literature ◽  
Double Hit Lymphoma ◽  
Double Hit

scholarly journals Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report

2021 ◽  
Vol 9 (2) ◽  
pp. 482-488
Author(s):  
Fan Xie ◽  
Li-Hui Zhang ◽  
Ya-Qing Yue ◽  
Lu-Lu Gu ◽  
Fei Wu
Keyword(s):  
Case Report ◽  
Double Hit Lymphoma ◽  
Double Hit

scholarly journals How I treat double-hit lymphoma

Blood ◽  
2017 ◽  
Vol 130 (5) ◽  
pp. 590-596 ◽  
Author(s):  
Jonathan W. Friedberg
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Central Nervous System Involvement ◽  
B Cell Lymphoma ◽  
World Health ◽  
Large B Cell Lymphoma ◽  
Double Hit Lymphoma ◽  
Increased Risk ◽  
Double Hit ◽  
Large B Cell

Abstract The 2016 revision of the World Health Organization (WHO) classification for lymphoma has included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell lymphoma with translocations involving myc and bcl-2 or bcl-6. These lymphomas, which occur in <10% of cases of diffuse large B-cell lymphoma, have been referred to as double-hit lymphomas (or triple-hit lymphomas if all 3 rearrangements are present). It is important to differentiate these lymphomas from the larger group of double-expressor lymphomas, which have increased expression of MYC and BCL-2 and/or BCL-6 by immunohistochemistry, by using variable cutoff percentages to define positivity. Patients with double-hit lymphomas have a poor prognosis when treated with standard chemoimmunotherapy and have increased risk of central nervous system involvement and progression. Double-hit lymphomas may arise as a consequence of the transformation of the underlying indolent lymphoma. There are no published prospective trials in double-hit lymphoma, however retrospective studies strongly suggest that aggressive induction regimens may confer a superior outcome. In this article, I review my approach to the evaluation and treatment of double-hit lymphoma, with an eye toward future clinical trials incorporating rational targeted agents into the therapeutic armamentarium.

Cytological features of hepatoid adenocarcinoma of the gallbladder: A case report with immunocytochemical analyzes

2018 ◽  
Vol 46 (8) ◽  
pp. 711-715
Author(s):  
Saya Yoshioka ◽  
Mitsuaki Ishida ◽  
Kimiaki Okano ◽  
Kaori Sandoh ◽  
Yusuke Ebisu ◽  
...  
Keyword(s):  
Case Report ◽  
Hepatoid Adenocarcinoma ◽  
Cytological Features

scholarly journals Primary pulmonary meningioma: A rare case report of aspiration cytological features and immunohistochemical assessment

2018 ◽  
Author(s):  
Kumi Ohashi‐Nakatani ◽  
Yasuo Shibuki ◽  
Mizuho Fujima ◽  
Reiko Watanabe ◽  
Akihiko Yoshida ◽  
...  
Keyword(s):  
Case Report ◽  
Rare Case ◽  
Rare Case Report ◽  
Cytological Features ◽  
Immunohistochemical Assessment

scholarly journals Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

2017 ◽  
Vol 35 (20) ◽  
pp. 2260-2267 ◽  
Author(s):  
Daniel J. Landsburg ◽  
Marissa K. Falkiewicz ◽  
Joseph Maly ◽  
Kristie A. Blum ◽  
Christina Howlett ◽  
...  
Keyword(s):  
Complete Remission ◽  
Intensive Therapy ◽  
Front Line ◽  
Term Survival ◽  
Disease Response ◽  
Line Therapy ◽  
Double Hit Lymphoma ◽  
Double Hit ◽  
First Complete Remission

Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefit of this treatment strategy is unclear. Methods Patients with DHL who achieved first complete remission following completion of front-line therapy with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and deemed fit for autoSCT, were included. A landmark analysis was performed, with time zero defined as 3 months after completion of front-line therapy. Patients who experienced relapse before or who were not followed until that time were excluded. Results Relapse-free survival (RFS) and overall survival (OS) rates at 3 years were 80% and 87%, respectively, for all patients (n = 159). Three-year RFS and OS rates did not differ significantly for autoSCT (n = 62) versus non-autoSCT patients (n = 97), but 3-year RFS was inferior in patients who received R-CHOP compared with intensive therapy (56% v 88%; P = .002). Three-year RFS and OS did not differ significantly for patients in the R-CHOP or intensive therapy cohorts when analyzed by receipt of autoSCT. The median OS following relapse was 8.6 months. Conclusion In the largest reported series, to our knowledge, of patients with DHL to achieve first complete remission, consolidative autoSCT was not associated with improved 3-year RFS or OS. In addition, patients treated with R-CHOP experienced inferior 3-year RFS compared with those who received intensive front-line therapy. When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population.

Sign in / Sign up

Export Citation Format

Share Document